BACKGROUND AND OBJECTIVES: @entity2682 is an oral antiepileptic agent with an unknown mechanism of action. Recent case reports have suggested that @entity2682 may be effective in the treatment of a variety of @entity9 states. This report presents baseline and follow-up data on ten @entity1 who were treated with @entity2682 when other pharmacologic interventions failed to relieve their @entity9 . METHODS: Ten @entity1 referred for treatment of unrelieved @entity9 in the head and neck region were included in this study. Baseline and follow-up information included measures of @entity158 intensity and @entity158 quality. All of the @entity1 were started on 300 mg @entity2682 three times per day, though daily doses of up to 2400 mg were required for @entity158 relief. RESULTS: Eight of the ten @entity1 had no @entity9 on follow-up, whereas the remaining 2 @entity1 reported only partial relief at follow-up. None of the @entity1 complained of side effects. @entity2682 was effective in alleviating steady @entity158 as well as lancinating @entity158 and @entity1931 . CONCLUSIONS: The results suggest that @entity2682 may be effective in the management of some cases of @entity9 in the head and neck. However, controlled, double-blind longitudinal studies are needed to evaluate this possibility.

Experience with @entity2682 for XXXX in the head and neck: report of ten cases.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1931 :: ('MESH:D006930', 'Disease') :: ['allodynia'] @entity2682 :: ('MESH:C040029', 'Chemical') :: ['Gabapentin', 'gabapentin'] @entity158 :: ('MESH:D010146', 'Disease') :: ['burning pain', 'pain'] @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain']
@entity9 :: (MESH:D009437,Disease) :: ['neuropathic pain']
